Ankylosing Spondylitis Market Analysis, Size, Share & Growth Forecast 2026–2034

Bimekizumab Dual IL-17A and IL-17F Blockade BE MOBILE Phase III Head-to-Head ASAS40 Superiority Over Adalimumab Has Established the Complete IL-17 Pathway Inhibition as the Next-Generation Anti-IL-17 Mechanism That the Single IL-17A Blockade of Secukinumab and Ixekizumab Does Not Achieve.Novartis's secukinumab MEASURE long-term data and Eli Lilly's ixekizumab COAST-V and COAST-W demonstrated ASAS40 response rates of 40-50% at 16 weeks and significantly greater MRI bone-edema and fat-lesion resolution than TNF inhibitors in head-to-head MRI analyses within the IMAS and SIAS programme. The bone-edema resolution advantage of IL-17A blockade over TNF inhibition in AS is mechanistically explained by IL-17's specific role in osteoblast activation and new bone formation at inflamed vertebral corners, and the greater suppression of IL-17-mediated bone remodelling produces more complete MRI normalisation than TNF blockade alone. European League Against Rheumatism and Assessment of Spondylarthritis International Society guidelines have progressively positioned IL-17A inhibitors alongside TNF inhibitors as first-line biologics in radiographic axSpA, and the 2022 EULAR update elevated IL-17A as the preferred mechanism in patients with significant skin or bowel comorbidity.

Secukinumab MEASURE Phase III 59 to 68 Percent ASAS20 Response With Sustained 52 and 104-Week CRP Normalisation Has Established the IL-17 Class as the Effective NSAID-Refractory and TNFi-Alternative Biologic That Addresses Both Clinical and Objective Inflammation in AS.AstraZeneca's ixekizumab COAST-X trial in nr-axSpA demonstrated 40% ASAS40 response and significant MRI improvement, earning FDA approval for non-radiographic axSpA as the first IL-17A inhibitor approved for this disease stage where TNF inhibitors had received approval through CIMZIA adalimumab-based programmes. The nr-axSpA population represents the earlier disease stage before syndesmophyte formation that defines radiographic AS, and early biologic therapy in this stage may prevent or delay the structural damage progression that occurs in 30-40% of nr-axSpA patients within 5-10 years. The clinical challenge of nr-axSpA biologic prescribing is the higher proportion of female patients with non-inflammatory pain contributors and the lower C-reactive protein sensitivity that makes patient selection for biologic therapy more uncertain than in established radiographic disease where objective inflammatory markers and radiographic findings guide treatment decisions.

Upadacitinib SELECT-AXIS 2 Phase III 40 to 45 Percent ASAS40 Response and MRI Sacroiliac Inflammation Reduction Has Provided the Oral JAK1 Inhibitor Alternative for the AS Patient Who Prefers Oral Targeted Therapy Over the Biologic Injection That Anti-TNF and Anti-IL-17 Require.UCB's bimekizumab demonstrated 47.7% ASAS40 response versus 41.0% for secukinumab at 16 weeks in BE AGILE, a numerical but not statistically powered superiority that has driven commercial investment in the dual IL-17A/F mechanism as potentially providing additive benefit in joints beyond what IL-17A-selective therapy achieves. The mechanistic rationale for IL-17F contribution to AS pathology involves the abundant IL-17F expression in synovial tissue at entheseal inflammatory sites that co-localises with IL-17A in the entheseal immune activation that drives spondylitis progression. The AS market differentiation for bimekizumab requires longer-term structural data demonstrating that dual IL-17A/F blockade achieves greater inhibition of new bone formation than IL-17A-selective agents, and the BE BRIGHT 5-year extension programme is generating the long-term radiographic data that will determine whether the numerical short-term advantage translates into clinically meaningful structural benefit.

For related market intelligence, see the Immunology Drug Market.